Overview
WARNING: As this organisation lists one or more EP accredited lobbyists, it may not be probable that its lobbying costs are lower than €10,000.
Lobbying Costs
9,999€
Financial year: Jan 2013 - Jan 2014
Lobbyists (Full time equivalent)
1 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Grünenthal GmbH (Grünenthal)
EU Transparency Register
67826544528-01 First registered on 14 Nov 2010
Goals / Remit
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company in the field of pain and thus to be a leader in therapy innovation.
Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 27 percent of revenues in 2013. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group has affiliates in 25 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2013, Grünenthal achieved revenues of €901 mn.
More information: www.grunenthal.comMain EU files targeted
Grünenthal supports the multistakeholder platform "Societal Impact of Pain" (SIP, www.sip-platofrm.eu). Furthermore Grünenthal activities in Brussels deal with issues related to healthcare, pain care, pharmaceuticals, innovation and research and intellectual property.
Address
Head Office
Zieglerstraße, 6
Aachen D-52099
GERMANY -
People
Total lobbyists declared
3
Employment time Lobbyists 50% 1 25% 2 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 12 Aug 2015
Name Start date End Date Ms Gudula Maria Petersen 14 Jun 2018 14 Jun 2019 Mr Theodorus Norbertus Maria van Rooij 17 Oct 2017 17 Oct 2018 Ms Gudula Maria Petersen 12 May 2017 09 May 2018 Mr Theodorus Norbertus Maria van Rooij 10 Oct 2016 05 Oct 2017 Ms Gudula Maria Petersen 29 Apr 2016 29 Apr 2017 Mr Theodorus Norbertus Maria van Rooij 24 Sep 2015 19 Sep 2016 Mr Konrad Labuschagne 21 May 2014 05 Jun 2015 Mr Konrad Labuschagne 25 May 2013 21 May 2014 Mrs Kristina Barinka 02 Mar 2013 29 Mar 2014 Mr Konrad Labuschagne 19 Jun 2012 17 Jun 2013 Mr Theodorus Norbertus Maria van Rooij 24 Mar 2012 01 Dec 2012 Mrs Kristina Barinka 24 Mar 2012 01 Dec 2012 Complementary Information
None declared
Person in charge of EU relations
Mr Norbert van Rooij (Governmental Affairs and Health Policy)
Person with legal responsibility
Mr Eric-Paul Pâques (Chairman of the Corporate Executive Board)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2013 - Jan 2014
Lobbying costs for closed financial year
9,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
None
Other activities
Grünenthal supports the multistakeholder platform "Societal Impact of Pain" (SIP, www.sip-platofrm.eu). Furthermore Grünenthal activities in Brussels deal with issues related to healthcare, pain care, pharmaceuticals, innovation and research and intellectual property.
Meetings
Meetings
None declared